Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE
Primary result · AOM initiationResult — go to the resultHazard ratio 9.50 CI 7.16–12.61Authors' conclusion
Screened women showed similar treatment adherence levels to non-screened once they started medication.
Study context
- Population
- Women aged 65–80 in the Region of Southern Denmark with FRAX ≥ 15%, invited to ROSE in 2010/2011women invited
- Participants
- 34,229 women
- Comparison
- Screened vs controls vs age-matched general population sample, adherence to anti-osteoporotic medication (AOM)
- Screenedn = 5,864
- Controlsn = 5,790reference
- Primary endpoint
- Adherence to AOM (initiation, implementation, persistence) and determinants of low adherence
- Follow-up
- 10-year follow-up
Methodological detailspopulation-based, age-matched general population sample, 10-year follow-up
- Population-based
- Age-matched general population sample
- 10-year follow-up
Primary result
AOM initiation · first year
Hazard ratio
9.50
CI 7.16–12.61
Screenedvs Controls
HR 9.50 (CI 7.16–12.61)
As reported in the abstract
Further findings
| Outcome | Screened | Controls | General population |
|---|---|---|---|
| 5-year persistence | 51-52% | 51-52% | 44% |
- 5-year persistence: similar in screened and controls (51-52%)
Determinants of discontinuation
- Immobilization, comorbidities and co-medications were key determinants of discontinuation in short and long term
- FRAX risk factors partly influenced AOM initiation in screened, with different patterns in other groups
Original publication
Long-term adherence to anti-osteoporosis medication and determinants of adherence in the population-based screening trial ROSE. Osteoporos Int. Published 24 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →